EastWest Bioscience Valuation
Is EAST undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Por debajo del valor justo
Muy por debajo del valor justo
Price-To-Earnings vs. similares
Price-To-Earnings vs. Industria
PM vs. Ratio Justo
Pronóstico de los analistas
Share Price vs Fair Value
What is the Fair Price of EAST when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Por debajo del valor justo: Datos insuficientes para calcular el valor razonable de EAST para el análisis de valoración.
Muy por debajo del valor justo: Datos insuficientes para calcular el valor razonable de EAST para el análisis de valoración.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for EAST?
Other financial metrics that can be useful for relative valuation.
What is EAST's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | CA$2.52m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 7x |
Enterprise Value/EBITDA | -2.2x |
PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does EAST's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 5.5x | ||
CLAS Claritas Pharmaceuticals | 0.4x | n/a | CA$944.7k |
HASH Simply Solventless Concentrates | 18.5x | n/a | CA$8.6m |
SILO Silo Wellness | 2.2x | n/a | CA$1.5m |
ATL Atlas Global Brands | 0.9x | n/a | CA$23.8m |
EAST EastWest Bioscience | 23.2x | n/a | CA$2.5m |
Price-To-Earnings vs. similares: EAST es caro según su Ratio Price-To-Earnings (23.2x) en comparación con la media de sus homólogos (10.9x).
Price to Earnings Ratio vs Industry
How does EAST's PE Ratio compare vs other companies in the North American Pharmaceuticals Industry?
Price-To-Earnings vs. Industria: EAST es caro en función de su Ratio Price-To-Earnings (23.2x) en comparación con la media del sector North American Pharmaceuticals (16.4x).
Price to Earnings Ratio vs Fair Ratio
What is EAST's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 23.2x |
Fair PE Ratio | n/a |
PM vs. Ratio Justo: Datos insuficientes para calcular EAST's Price-To-Earnings Fair Ratio para el análisis de valoración.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Pronóstico de los analistas: Datos insuficientes para mostrar el pronóstico de precios.